Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 5/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2191501 | 0.93 | SETD7 (0.47) | SETD7HTTL3MBTL1HCRTR1HCRTR2 | |
| SCHEMBL25120232 | 0.88 | GPR119 (0.48) | HCRTR1HCRTR2LMNAALDH1A1DRD2 | |
| SCHEMBL30318930 | 0.88 | GPR119 (0.48) | HCRTR1HCRTR2LMNAALDH1A1DRD2 | |
| SCHEMBL25120241 | 0.80 | MEN1 (0.46) | HTTL3MBTL1HCRTR1HCRTR2MGLL | |
| SCHEMBL25120379 | 0.80 | NPC1 (0.54) | HTTHCRTR1HCRTR2LMNAALDH1A1 | |
| SCHEMBL12508557 | 0.80 | MAPK1 (0.47) | HTTL3MBTL1ALDH1A1GHSR | |
| SCHEMBL2197433 | 0.79 | HCRTR1 (0.45) | HTTHCRTR1HCRTR2LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL2196480 | 0.79 | HCRTR1 (0.44) | HTTHCRTR1HCRTR2LMNAALDH1A1 | |
| SCHEMBL2194541 | 0.78 | F10 (0.48) | HTTHCRTR1HCRTR2LMNAALDH1A1 | |
| SCHEMBL30318932 | 0.78 | F10 (0.48) | HTTHCRTR1HCRTR2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | SETD7 343/4885HTT 2211/4885L3MBTL1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.